Seelos Therapeutics Inc (SEEL)
3.90
-1.10
(-22.00%)
USD |
NASDAQ |
Sep 27, 16:00
3.83
-0.07
(-1.79%)
After-Hours: 20:00
Seelos Therapeutics SG&A Expense (Annual): 12.58M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.58M |
| December 31, 2022 | 12.30M |
| December 31, 2021 | 15.02M |
| December 31, 2020 | 7.775M |
| December 31, 2019 | 7.559M |
| December 31, 2018 | 7.928M |
| December 31, 2017 | 7.21M |
| December 31, 2016 | 7.778M |
| December 31, 2015 | 10.52M |
| December 31, 2014 | 11.42M |
| December 31, 2013 | 13.55M |
| December 31, 2012 | 15.34M |
| December 31, 2011 | 11.45M |
| December 31, 2010 | 10.15M |
| Date | Value |
|---|---|
| December 31, 2009 | 4.196M |
| December 31, 2008 | 5.721M |
| December 31, 2007 | 5.634M |
| December 31, 2006 | 5.571M |
| December 31, 2005 | 6.878M |
| December 31, 2004 | 6.980M |
| December 31, 2003 | 5.901M |
| December 31, 2002 | 6.065M |
| December 31, 2001 | 4.77M |
| December 31, 2000 | 3.210M |
| December 31, 1999 | 1.762M |
| December 31, 1998 | |
| December 31, 1997 | 1.825M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.559M
Minimum
2019
15.02M
Maximum
2021
11.05M
Average
12.30M
Median
2022
SG&A Expense (Annual) Benchmarks
| 180 Life Sciences Corp | 10.69M |
| Cassava Sciences Inc | 16.53M |
| Cara Therapeutics Inc | 27.65M |
| Citius Pharmaceuticals Inc | 21.91M |
| Moleculin Biotech Inc | 10.02M |